nach oben

Lung

Erschienen in:

01.02.2008 | State of the Art Review

The Economic Impact of Obstructive Sleep Apnea

verfasst von: Nayef AlGhanim, Vikram R. Comondore, John Fleetham, Carlo A. Marra, Najib T. Ayas

Erschienen in: Lung | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Untreated obstructive sleep apnea (OSA) increases healthcare utilization and is associated with reduced work performance and occupational injuries. The economic burden related to untreated OSA is substantial, accounting for billions of dollars per year. Furthermore, therapy of OSA is an extremely cost-efficient use of healthcare resources, comparing highly favorably with other commonly funded medical therapies. Governments, transportation agencies, industry, and insurance companies need to be better informed concerning the economic impact of untreated OSA and the benefits of therapy.

Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 32:1230–1235CrossRef

Ip M, Chung KF, Chan KN, Lam SP, Lee K (1999) Previously unrecognized obstructive sleep apnea in Chinese subjects with essential hypertension. Lung 177(6):391–400PubMedCrossRef

Shamsuzzaman ASM, Gersh BJ, Somers V (2003) Obstructive sleep apnea – implications for cardiac and vascular disease. JAMA 290(14):1906-1919PubMedCrossRef

Young T, Peppard PE, Gottlieb DJ (2002) Epidemiology of obstructive sleep apnea – a population health perspective. Am J Respir Crit Care Med 165:1217–1239PubMedCrossRef

Grunstein RR, Stenlof K, Hedner JA, Sjostrom L (1995) Impact of self-reported sleep-breathing disturbances on psychosocial performance in the Swedish Obese Subjects (SOS) study. Sleep 18:635–643PubMed

Ulfberg J, Carter N, Talback M, Edling C (1996) Excessive daytime sleepiness at work and subjective work performance in the general population and among heavy snorers and patients with obstructive sleep apnea. Chest 110:659–663PubMedCrossRef

Mulgrew AT, Ryan CF, Fleetham JA, Cheema R, Fox N, Koehoorn M, FitzGerald JM, Marra C, Ayas NT (2007) The impact of obstructive sleep apnea and daytime sleepiness on work limitation. Sleep Med [epub ahead of print]

Lerner D, Amick BC, Lee JC, Rooney T, Rogers WH, Chang H, Berndt ER (2003) Relationship of employee-reported work limitations to work productivity. Med Care 41(5):649–659PubMedCrossRef

Ulfberg J, Jonsson R, Edling C (1999) Improvement of subjective work performance among obstructive sleep apnea patients after treatment with continuous positive airway pressure. Psychiatry Clin Neurosci 53(6):677–679PubMedCrossRef

10.

Scharf MB, Stover R, McDannold MD, Spinner O, Berkowitz DV, Conrad C (1999) Outcome evaluation of long-term nasal continuous positive airway pressure therapy in obstructive sleep apnea. Am J Ther 6(6):293–297PubMedCrossRef

11.

Arai H, Furuta H, Kosaka K, Kaneda R, Koshino Y, Sano J, Kumagai S, Yamamoto E (1998) Changes in work performances in obstructive sleep apnea patients after dental appliance therapy. Psychiatry Clin Neurosci 52(2):224–225PubMedCrossRef

12.

Patel SR, White DP, Malhotra A, Stanchina ML, Ayas NT (2003) Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med 163(5):565–571PubMedCrossRef

13.

Anon (2007) Fatal Occupational Injuries—United States, 2005. MMWR Morbid Mortal Wkly Rep 56(13):297–301

14.

Chouri-Pontarollo N, Borel JC, Tamisier R, Wuyam B, Levy P, Pepin JL (2007) Impaired objective daytime vigilance in obesity-hypoventilation syndrome: impact of noninvasive ventilation. Chest 131(10):148–155PubMedCrossRef

15.

Howard ME, Desai AV, Grunstein RR, Hukins C, Armstrong JG, Joffe D, Swann P, Campbell DA, Pierce RJ (2004) Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers. Am J Respir Crit Care Med 170(9):1014–1021PubMedCrossRef

16.

Ulfberg J, Carter N, Edling C (2000) Sleep-disordered breathing and occupational accidents. Scand J Work Environ Health 26(3):237–242PubMed

17.

Lindberg E, Carter N, Gislason T, Janson C (2001) Role of snoring and daytime sleepiness in occupational accidents. Am J Respir Crit Care Med 164:2031–2035PubMed

18.

Spengler SE, Browning SR, Reed DB (2004) Sleep deprivation and injuries in part-time Kentucky farmers: impact of self reported sleep habits and sleep problems on injury risk. Am Assoc Occup Health Nurses J 52(9):373–382

19.

George CF (2001) Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 56:508–512PubMedCrossRef

20.

Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J (1999) The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 340(11):847–851PubMedCrossRef

21.

Sassani A, Findley LJ, Kryger M, Goldlust E, George C, Davidson TM (2004) Reducing motor-vehicle collisions, costs, and fatalities by treating obstructive sleep apnea syndrome. Sleep 27(3):453–458PubMed

22.

Hillman DR, Murphy AS, Antic R, Pezzullo L (2006) The economic cost of sleep disorders. Sleep 29(3):299–305PubMed

23.

Beasley R (2002) The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 109:S482–S489PubMedCrossRef

24.

Mannino DM, Braman S (2007) The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4:502–506PubMedCrossRef

25.

American Diabetes Association (2003) Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917–932CrossRef

26.

Bahammam A, Delaive K, Ronald J, Manfreda J, Roos L, Kryger MH (1999) Health care utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. Sleep 22(6):740–747PubMed

27.

Kapur V, Blough DK, Sandblom RE, Hert R, de Maine JB, Sullivan SD, Psaty BM (1999) The medical cost of undiagnosed sleep apnea. Sleep 22(6):749–755PubMed

28.

Tarasiuk A, Greenberg-Dotan S, Brin YS, Simon T, Tal A, Reuveni H (2005) Determinants affecting health-care utilization in obstructive sleep apnea syndrome patients. Chest 128:1310–1314PubMedCrossRef

29.

Albarrak M, Banno K, Sabbagh AA, Delaive K, Walld R, Manfreda J, Kryger MH (2005) Utilization of healthcare resources in obstructive sleep apnea syndrome: a 5-year follow-up study in men using CPAP. Sleep 28(10):1306–1311PubMed

30.

Ubel PA, Hirth RA, Chernew ME, Fendrick AM (2003) What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 163(14):1637–1641PubMedCrossRef

31.

Tousignant P, Cosio MG, Levy RD, Groome PA (1994) Quality adjusted life years added by treatment of obstructive sleep apnea. Sleep 17(1):52–60PubMed

32.

Mar J, Rueda JR, Duran-Cantolla J, Schechter C, Chilcott J (2003) The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J 21(3):515–522PubMed

33.

Ayas NT, Fitzgerald M, Fleetham JA, White DP, Schultzer M Ryan F, Ghaeli R, Mercer GW, Cooper P, Tan MCY, Marra CA (2006) Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med 166:977–984PubMedCrossRef

34.

Tan MC, Ayas NT, Mulgrew A, Cortes L, FitzGerald JM, Fleetham JA, Schulzer M, Ryan CF, Ghaeli R, Cooper P, Marra CA (2007) Cost-effectiveness of CPAP therapy for obstructive sleep apnea hypopnea in British Columbia. Can Respir J (in press)

35.

Parish JM, Lyng PJ (2003) Quality of life in bed partners of patients with obstructive sleep apnea or hypopnea after treatment with continuous positive airway pressure. Chest 124(3):942–947PubMedCrossRef

36.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC (2000) Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132(10):769–779PubMed

37.

Wong JB (2004) Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 22(5 Suppl 35):S65–S70PubMed

38.

Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE, National Emphysema Treatment Trial Research Group (2003) Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 348(21):2092–2102PubMedCrossRef

39.

Jenkinson C, Davies RJ, Mullins R, Stradling JR (1999) Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized prospective parallel trial. Lancet 353(9170):2100–2105PubMedCrossRef

40.

Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053PubMed

41.

Flemons WW, Douglas NJ, Kuna ST, Rodenstein DO, Wheatley J (2004) Access to diagnosis and treatment of patients with suspected sleep apnea. Am J Respir Crit Care Med 169:668–672PubMedCrossRef

42.

Fleetham J, Ayas N, Bradley D, Ferguson K, Fitzpatrick M, George C, Hanley P, Hill F, Kimoff J, Kryger M, Morrison D, Series F, Tsai W (2006) Canadian Thoracic Society Guidelines: Diagnosis and treatment of sleep disordered breathing in adults. Can Respir J 13(7):387–392PubMed

43.

Mulgrew AT, Fox N, Ayas NT, Ryan CF (2007) Ambulatory clinical algorithm for diagnosis and CPAP titration in obstructive sleep apnea: a randomized controlled trial. Ann Intern Med 146:157–166PubMed

44.

Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290:781–789PubMedCrossRef

45.

Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS (2006) Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 9:227–235PubMedCrossRef

46.

Vergel YB, Palmer S, Asseburg C, Fenwick E, de Belder M, Abrams K, Sculpher M (2007) Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart 93:1238–1243CrossRef

47.

Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353:1471–1480PubMedCrossRef

48.

Cox CE, Carson SS, Govert JA, Chelluri L, Sanders GD (2007) An economic evaluation of prolonged mechanical ventilation. Crit Care Med 35:1918–1927PubMedCrossRef

49.

NETT Investigators (2003) Cost-effectiveness of lung volume reduction surgery for patients with severe emphysema. N Engl J Med 348:2092–2102CrossRef

Titel: The Economic Impact of Obstructive Sleep Apnea
verfasst von: Nayef AlGhanim
Vikram R. Comondore
John Fleetham
Carlo A. Marra
Najib T. Ayas
Publikationsdatum: 01.02.2008
Verlag: Springer-Verlag
Erschienen in: Lung / Ausgabe 1/2008
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-007-9055-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Truncal Adiposity and Lung Function in Older Black Women

The Utility of Spirometry in Diagnosing Pulmonary Restriction

Impact of Thrombophilic Genetic Factors on Pulmonary Embolism: Early Onset and Recurrent Incidences

Reviewers

In Vitro Mechanisms of Lovastatin on Lung Cancer Cell Lines as a Potential Chemopreventive Agent